Last update April 5, 2022

Ubrogepant

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a calcitonin gene-related peptide receptor antagonist. It is ndicated for the treatment of migraine. Oral administration once or twice a day.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (high percentage of protein binding, moderately high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ubrogepant in other languages or writings:

  • C29H26F3N5O3 (Molecular formula)
  • N02CD04 (ATC Code/s)

Group

Ubrogepant belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ubrogepant in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 550 daltons
Protein Binding 87 %
VD 5 l/Kg
pKa 11.74 -
Tmax 0.7 - 1.5 hours
5 - 7 hours

References

  1. FDA. Ubrogepant (Ubrelvy). Drug Summary 2019 Full text (in our servers)

Total visits

136

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM